Skip to main content

Table 1 Demographic data

From: Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

History (risk factors) EES group BVS group Test p value Sig.
No. = 40 No. = 20
Age Mean ± SD 57.38 ± 6.98 56.15 ± 9.25 0.574b 0.568 NS
Range 45–75 34–80
Sex Male 37 (92.5 %) 19 (95%) 0.463b 0.457 NS
Female 5 (12.5 %) 1 (5%)
DM Negative 19 (47.5%) 8 (40.0%) 0.881a 0.459 NS
Positive 21 (52.5) 12 (60.0%)
Hyperlipidemia Negative 5 (12.5%) 0 (0.0%) 2.727a 0.099 NS
Positive 35 (87.5%) 20 (100.0%)
HTN Negative 17 (42.5%) 6 (30.0%) 0.881a 0.348 NS
Positive 23 (57.5%) 14 (70.0%)
History of MI Negative 24 (60.0%) 14 (70.0%) 0.574a 0.449 NS
Positive 16 (40.0%) 6 (30.0%)
Family history of premature CAD Negative 31 (77.5%) 17 (85.0%) 0.469a 0.494 NS
Positive 9 (22.5%) 3 (15.0%)
Previous PCI, CABG Negative 27 (67.5%) 17 (85.0%) 2.088a 0.148 NS
Positive 13 (32.5%) 3 (15.0%)
  1. NS non-significant, S significant, HTN hypertension, MI myocardial infraction, CAD coronary artery disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft
  2. aChi-square test
  3. bIndependent t test